Komori

Daicel Corporation

4202Materials and ChemicalsMid cap
1,444JPY+0.9%
★ Watch (sign-up required)
Price history
¥1,444Latest+84.4%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Daicel Group consists of Daicel Corporation, 58 subsidiaries and 11 affiliated companies. Its principal business areas comprise five segments—Medical & Healthcare, Smart, Safety, Materials and Engineering Plastics—as well as Other. The Group has a global supply network, including overseas operations, and has set out Accelerate 2030 as its future strategy. It focuses on sustainability and regulatory compliance, vertical and horizontal value creation, digital transformation, and the provision of environmentally responsible materials and technologies. The financial data is organized based on fiscal 2026 results by segment and region.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
39.61How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.97How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
2.4%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥371bnShare price × number of shares. The value of the entire company.
Equity ratio
42.5%The proportion of assets funded by money that does not have to be repaid.
Operating margin
9.2%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
5.2%The average annual growth in sales over the past three years.
What to watch next
The absorption-type company split and business succession involving Polyplastics in April 2026, marking the execution phase for integration-related decision-making and improved governance efficiency
April 2026 (completed/recent)Impact MediumLikelihood Medium
A further update to the outlook in response to the factors behind the fiscal 2026 earnings downgrade confirmed in investor news, including foreign exchange losses, market conditions and demand
Timing of earnings and earnings forecast disclosures during 2026Impact HighLikelihood High
Expansion of CycloVia-certified products, which numbered 16 as of the end of March 2026, and progress in the sales and adoption of related products
From fiscal 2026 onward (continued expansion of certifications and the lag before this is reflected in commercial distribution)Impact MediumLikelihood Medium
Disclosures on progress in indicators showing the ramp-up of investment projects in the medical and semiconductor fields, including chiral columns, DDS, semiconductor materials and resist materials
Fiscal 2026 disclosures (quarterly)Impact MediumLikelihood Medium
What to watch next
Loading
Who owns itTop holders total 97.6%
Listed holders 97.6%Everyone else 2.4%
Total shareholders49.92%
The Master Trust Bank of Japan, Ltd. (Trust Account)13.81%
日本カストディ銀行(信託口)10.36%
日本生命保険(相)6.81%
NORTHERN TRUST CO. (AVFC) RE SILCHESTER INTERNATIONAL INVESTORS3.79%
FUJIFILM Holdings Corporation3.28%
ダイセルグループ従業員持株会2.65%
NORTHERN TRUST CO.(AVFC) RE U.S. TAX EXEMPTED PENSION FUNDS2.49%
2 other listed holders4.47%
Who owns it
HolderOwnership (%)
Total shareholders49.92
The Master Trust Bank of Japan, Ltd. (Trust Account)13.81
日本カストディ銀行(信託口)10.36
日本生命保険(相)6.81
NORTHERN TRUST CO. (AVFC) RE SILCHESTER INTERNATIONAL INVESTORS3.79
FUJIFILM Holdings Corporation3.28
ダイセルグループ従業員持株会2.65
NORTHERN TRUST CO.(AVFC) RE U.S. TAX EXEMPTED PENSION FUNDS2.49
2 other listed holders4.47
This company's documents
Filings
Timely disclosures